The level of Interleukin-6 is increased in COVID-19 and other viral infection-associated diseases.
•
Interleukin-6 is involved in immunometabolic reprogramming in several viral infection-associated diseases.
•
Targeting metabolic pathways could control the release of Interleukin-6 in COVID-19 patients.
•
Interleukin-6-elicited inflammatory response is closely associated with metabolic disorder in patients with viral infection.
Abstract
Interleukin-6 (IL-6) is a highly pleiotropic glycoprotein factor that can modulate innate and adaptive immunity as well as various aspects of metabolism, including glycolysis, fatty acid oxidation and oxidative phosphorylation. Recently, the expression and release of IL-6 is shown to be significantly increased in numerous diseases related to virus infection, and this increase is positively correlated with the disease severity. Immunity and metabolism are two highly integrated and interdependent systems, the balance between them plays a pivotal role in maintaining body homeostasis. IL-6-elicited inflammatory response is found to be closely associated with metabolic disorder in patients with viral infection. This brief review summarizes the regulatory role of IL-6 in immunometabolic reprogramming among seven viral infection-associated diseases.
Keywords
Interleukin-6
Immunometabolic reprogramming
Viral infection
COVID-19
Data availability
No data was used for the research described in the article.